Hu Jing, Ma Li, Yang Zeng-Ye
Department of Neurology, Ankang People's Hospital, Ankang.
Department of Neurology, Yanan University Affiliated Hospital.
Medicine (Baltimore). 2020 Jun 26;99(26):e20608. doi: 10.1097/MD.0000000000020608.
This study aims to assess the efficacy and safety of citalopram for the treatment of patients with post-stroke depression (PSD).
We will comprehensively search Cochrane Library, PUBEMD, EMBASE, WorldSciNet, Web of Science, VIP Database, CBM database, and China National Knowledge Infrastructure. The search period is limited from the construction of each database to the February 1, 2020. No language and publication status are limited. Two investigators will independently carry out study choosing, data extraction, study methodological quality assessment, and quality of evidence. A third investigator will help to resolve any disagreements between 2 investigators. RevMan 5.3 software will be employed for statistical analysis.
This study will summarize the up-to-date evidence and synthesize the data to explore the efficacy and safety of citalopram for patients with PSD.
The results of this study may present helpful evidence to determine whether citalopram is an effective management for patients with PSD.
PROSPERO CRD42020171015.
本研究旨在评估西酞普兰治疗脑卒中后抑郁（PSD）患者的疗效和安全性。
我们将全面检索Cochrane图书馆、PUBEMD、EMBASE、WorldSciNet、科学网、维普数据库、中国生物医学文献数据库和中国知网。检索期限从各数据库建库至2020年2月1日。不限语言和出版状态。两名研究者将独立进行研究选择、数据提取、研究方法学质量评估和证据质量评估。第三名研究者将帮助解决两名研究者之间的任何分歧。将使用RevMan 5.3软件进行统计分析。
本研究将总结最新证据并综合数据，以探讨西酞普兰治疗PSD患者的疗效和安全性。
本研究结果可能为确定西酞普兰是否为PSD患者的有效治疗方法提供有用证据。
PROSPERO注册号：PROSPERO CRD42020171015。
